Our investment team is led by professionals with advanced medical and scientific backgrounds, paired with financial acumen to evaluate the medical and business aspects of each investment. The extensive expertise and consistent discipline across accounting, compliance, risk management and client service, is displayed by our first-rate operations team.

Team

Our Team

Investment Professionals

  • Behzad Aghazadeh

    Behzad Aghazadeh

    PhD | Managing Partner & Portfolio Manager

    Behzad has more than 20 years of experience in the biopharmaceutical industry, with over 10 years of experience as an institutional investor. He began his career in healthcare as a research scientist, later joining Booz Allen as a management consultant, where he led major strategic and operational initiatives for companies in the pharmaceutical and biotechnology industries. Behzad currently serves as the Chairman of Immunomedics, a clinical-stage biopharmaceutical company developing targeted therapies for the treatment of cancers and other diseases with high unmet medical need. Behzad received his Master’s degree in Physics from the Ludwig-Maximilians-University (Munich, Germany) and a PhD from Cornell University in Biochemistry & Biophysics.

    Behzad Aghazadeh

    Behzad has more than 20 years of experience in the biopharmaceutical industry, with over 10 years of experience as an institutional investor. He began his career in healthcare as a research scientist, later joining Booz Allen as a management consultant, where he led major strategic and operational initiatives for companies in the pharmaceutical and biotechnology industries. Behzad currently serves as the Chairman of Immunomedics, a clinical-stage biopharmaceutical company developing targeted therapies for the treatment of cancers and other diseases with high unmet medical need. Behzad received his Master’s degree in Physics from the Ludwig-Maximilians-University (Munich, Germany) and a PhD from Cornell University in Biochemistry & Biophysics.

  • Senai Asefaw

    Senai Asefaw

    MD | Director

    Senai received his M.D. from Yale University School of Medicine. Senai also has an MBA from Yale University School of Management and completed his undergraduate studies at Harvard University. Senai is a Board Certified internist practicing at Yale-New Haven Hospital and a Clinical Assistant Professor of Medicine at Yale University School of Medicine. Senai joined the Avoro Capital team in 2014 and is primarily involved in evaluating mid-to late-stage stage biotechnology investment opportunities.

    Senai Asefaw

    Senai received his M.D. from Yale University School of Medicine. Senai also has an MBA from Yale University School of Management and completed his undergraduate studies at Harvard University. Senai is a Board Certified internist practicing at Yale-New Haven Hospital and a Clinical Assistant Professor of Medicine at Yale University School of Medicine. Senai joined the Avoro Capital team in 2014 and is primarily involved in evaluating mid-to late-stage stage biotechnology investment opportunities.

  • Andy Washkowitz

    Andy Washkowitz

    PhD | Director

    Andy holds a B.A. from Harvard University, and earned his M.A. and PhD in genetics from Columbia University. While at Columbia, Andy was a fellow at the Technology Ventures office, focusing on out-licensing discoveries from Columbia labs. After graduate school, Andy worked in sell-side equity research at Stifel focusing in the biotechnology sector. Andy joined the Avoro Capital team in 2015 and is primarily involved in evaluating platform technologies and early clinical development programs.

    Andy Washkowitz

    Andy holds a B.A. from Harvard University, and earned his M.A. and PhD in genetics from Columbia University. While at Columbia, Andy was a fellow at the Technology Ventures office, focusing on out-licensing discoveries from Columbia labs. After graduate school, Andy worked in sell-side equity research at Stifel focusing in the biotechnology sector. Andy joined the Avoro Capital team in 2015 and is primarily involved in evaluating platform technologies and early clinical development programs.

  • Kasia Konopacki

    Kasia Konopacki

    PhD | Analyst

    Kasia received her PhD from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences, where she focused on the study of regulatory T cell function in health and disease. During her time at MSKCC, Kasia was on the executive board of InSITE, a top fellowship program focused on advising early-stage companies on market strategy and financing, and worked with Mid-Atlantic Bio Angels, a life science angel investing group. Kasia joined Avoro Capital in 2018 and will focus her research efforts at on immunology and early clinical development programs.

    Kasia Konopacki

    Kasia received her PhD from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences, where she focused on the study of regulatory T cell function in health and disease. During her time at MSKCC, Kasia was on the executive board of InSITE, a top fellowship program focused on advising early-stage companies on market strategy and financing, and worked with Mid-Atlantic Bio Angels, a life science angel investing group. Kasia joined Avoro Capital in 2018 and will focus her research efforts at on immunology and early clinical development programs.

  • Robert Raphael

    Robert Raphael

    Trader

    Robert has over 10 years of trading and operations experience. Prior to joining Avoro, Robert helped launch and was Head Trader at Jafra Capital Management. Before Jafra, he was a Trader at Jericho Capital Asset Management. He began his career on the Trade Operations team at TPG Axon. Robert holds a BA Cum Laude in Political Science from the University of Rochester. Robert joined Avoro Capital in 2019.

    Robert Raphael

    Robert has over 10 years of trading and operations experience. Prior to joining Avoro, Robert helped launch and was Head Trader at Jafra Capital Management. Before Jafra, he was a Trader at Jericho Capital Asset Management. He began his career on the Trade Operations team at TPG Axon. Robert holds a BA Cum Laude in Political Science from the University of Rochester. Robert joined Avoro Capital in 2019.

  • Max Isberg

    Max Isberg

    Analyst

    Max holds a B.S. from Tufts University. He graduated Summa Cum Laude in 2016, majoring in math and economics. After graduating, he worked for Apex Capital Holdings, where he was a trader/analyst managing a long/short equity portfolio focused on biotechnology and pharmaceutical names. Max joined Avoro Capital in 2019 and will focus on quantitative analysis and portfolio analytics.

    Max Isberg

    Max holds a B.S. from Tufts University. He graduated Summa Cum Laude in 2016, majoring in math and economics. After graduating, he worked for Apex Capital Holdings, where he was a trader/analyst managing a long/short equity portfolio focused on biotechnology and pharmaceutical names. Max joined Avoro Capital in 2019 and will focus on quantitative analysis and portfolio analytics.


Finance and Operations

  • Scott Epstein

    Scott Epstein

    Chief Financial Officer / Chief Compliance Officer

    Scott is responsible for the operational infrastructure across the Avoro Capital Advisors business and directly oversees the compliance and regulatory responsibilities for the firm. He has been working in the financial industry for over 20 years and most recently spent 11 years at HSBC where he was the Regional Head of the Americas, responsible for the management and development of the HSBC Securities Services businesses in the Americas Region focused primarily on Alternative Asset Managers. Prior to joining HSBC, Scott was a Vice President at Sanford C. Bernstein & Co., Inc., an investment research and management firm, where he was responsible for overseeing the operations of various investment products. Scott joined Avoro Capital in 2014.

    Scott Epstein

    Scott is responsible for the operational infrastructure across the Avoro Capital Advisors business and directly oversees the compliance and regulatory responsibilities for the firm. He has been working in the financial industry for over 20 years and most recently spent 11 years at HSBC where he was the Regional Head of the Americas, responsible for the management and development of the HSBC Securities Services businesses in the Americas Region focused primarily on Alternative Asset Managers. Prior to joining HSBC, Scott was a Vice President at Sanford C. Bernstein & Co., Inc., an investment research and management firm, where he was responsible for overseeing the operations of various investment products. Scott joined Avoro Capital in 2014.

  • Stacia Rogers

    Stacia Rogers

    CAIA | Investor Relations & Marketing

    Stacia has over 15 years of client management and investment-related experience. Over the course of her career, Stacia has served as an Investor Relations and Marketing professional with three hedge funds; Serengeti Asset Management, Knighthead Capital and Lazard Asset Management. Additionally, Stacia was a Product Specialist with the Private Funds Group at PineBridge Investments and began her career as an Institutional Investor on behalf of Wells Fargo’s corporate pension plan. Stacia holds a B.S.B. and M.B.A. from the University of Minnesota, Carlson School of Management and is a Chartered Alternative Investment Analyst. Stacia joined Avoro Capital in 2018.

    Stacia Rogers

    Stacia has over 15 years of client management and investment-related experience. Over the course of her career, Stacia has served as an Investor Relations and Marketing professional with three hedge funds; Serengeti Asset Management, Knighthead Capital and Lazard Asset Management. Additionally, Stacia was a Product Specialist with the Private Funds Group at PineBridge Investments and began her career as an Institutional Investor on behalf of Wells Fargo’s corporate pension plan. Stacia holds a B.S.B. and M.B.A. from the University of Minnesota, Carlson School of Management and is a Chartered Alternative Investment Analyst. Stacia joined Avoro Capital in 2018.

  • Diane Chien

    Diane Chien

    CPA | Hedge Fund Controller

    Prior to joining Avoro, Diane spent nine years as Vice President, Assistant Controller of the distressed hedge fund business at MatlinPatterson Global Advisers LLC. Diane began her career at PricewaterhouseCoopers as a Tax Associate in Private Company Services and Senior Associate in the Alternatives Assurance practice. She holds a B.S. in Finance and Accounting from New York University Stern School of Business and is a Certified Public Accountant in the State of New York. Diane joined Avoro Capital in 2016.

    Diane Chien

    Prior to joining Avoro, Diane spent nine years as Vice President, Assistant Controller of the distressed hedge fund business at MatlinPatterson Global Advisers LLC. Diane began her career at PricewaterhouseCoopers as a Tax Associate in Private Company Services and Senior Associate in the Alternatives Assurance practice. She holds a B.S. in Finance and Accounting from New York University Stern School of Business and is a Certified Public Accountant in the State of New York. Diane joined Avoro Capital in 2016.

  • Erica Horowitz

    Erica Horowitz

    Office Manager & Operational Support

    Since receiving her B.A. from Fordham University in 2010, Erica has served as an assistant to high-level executives and an office manager for teams of up to 70 employees within the publishing, real estate, and finance industries. She is also a certified professional life coach working with millennial women on pursuing their career and creative aspirations with less stress and more fulfillment. Erica joined Avoro Capital in 2016.

    Erica Horowitz

    Since receiving her B.A. from Fordham University in 2010, Erica has served as an assistant to high-level executives and an office manager for teams of up to 70 employees within the publishing, real estate, and finance industries. She is also a certified professional life coach working with millennial women on pursuing their career and creative aspirations with less stress and more fulfillment. Erica joined Avoro Capital in 2016.